|
FDA Orders Clinical Hold on Biologic Trial
A Phase II trial of a treatment designed to repair heart muscle in patients with heart failure has been placed on clinical hold at the FDA’s direction after a patient suffered a serious adverse event (SAE) related to “anesthesia management,” Aastrom Biosciences says.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives